Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 6/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20378741 | 0.86 | CA12 (0.42) | CA12CA1CA2CA4CA6 | |
| SCHEMBL4874863 | 0.84 | MEN1 (0.48) | KMT2A | |
| SCHEMBL31111349 | 0.83 | KDM4E (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16312194 | 0.82 | PKM (0.39) | CA12CA1CA2CA4CA6 | |
| SCHEMBL8940576 | 0.81 | CA12 (0.51) | CA12CA1CA2CA4CA6 | |
| SCHEMBL29724091 | 0.81 | CA12 (0.43) | CA12CA1CA2CA4CA6 | |
| SCHEMBL8696286 | 0.79 | CA12 (0.45) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3964477 | 0.79 | HTT (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL4129848 | 0.79 | HTT (0.49) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3296656 | 0.79 | CA12 (0.41) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116144011-B | Polyethylene glycol tail chain water-soluble polyphenol polymer and preparation method and application thereof | 上海师范大学 | 2025-02-28 | — | — | CN | claimed |
| CN-116144011-A | Polyethylene glycol tail chain water-soluble polyphenol polymer and preparation method and application thereof | 上海师范大学 | 2023-05-23 | — | — | CN | claimed |
| CN-116144011-B | Polyethylene glycol tail chain water-soluble polyphenol polymer and preparation method and application thereof | 上海师范大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-117720515-B | GASDERMINS protein PROTAC degradation agent and preparation method and application thereof | 中国药科大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-117720515-A | Gasdenmins protein PROTAC degradation agent and preparation method and application thereof | 中国药科大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-116144011-A | Polyethylene glycol tail chain water-soluble polyphenol polymer and preparation method and application thereof | 上海师范大学 | 2023-05-23 | — | — | CN | disclosed |
| US-9359395-B2 | Prodrugs of steroidal CYP17 inhibitors/antiandrogens | TOKAI PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| EP-3023433-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | Tokai Pharmaceuticals, Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2393827-B1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS INC (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20140371181-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20110312916-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2393827-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | Tokai Pharmaceuticals, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091306-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | disclosed |
| US-7700646-B2 | Compounds for use in the treatment of infection | THE UNIVERSITY OF LONDON, SCHOOL OF PHARMACY (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20070021384-A1 | Compounds for use in the treatment of infection | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371181-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP21A2, CYP17A1, CYP19A1 | CA12 2788/4885CA1 3165/4885CA2 2851/4885 |
| US-20110312916-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP21A2, CYP17A1, CYP19A1 | CA12 2382/4885CA1 2394/4885CA2 2889/4885 |
| US-20070021384-A1 | Compounds for use in the treatment of infection | C9, APEH, GRHPR | CA12 4195/4885CA1 3883/4885CA2 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.